| scholarly article | Q13442814 |
| P50 | author | Sebastian L Johnston | Q57328383 |
| Saffron Willis-Owen | Q86177895 | ||
| Toby Maher | Q42886895 | ||
| Michael J Cox | Q43242747 | ||
| Miriam F Moffatt | Q56959224 | ||
| P2093 | author name string | David A Schwartz | |
| Athol U Wells | |||
| Elissa Murphy | |||
| Patrick Mallia | |||
| Anne-Marie Russell | |||
| William O C Cookson | |||
| Kirsty E Russell | |||
| Phillip L Molyneaux | |||
| P2860 | cites work | Analysis of the lung microbiome in the "healthy" smoker and in COPD | Q21091065 |
| Disordered microbial communities in asthmatic airways | Q21562589 | ||
| QIIME allows analysis of high-throughput community sequencing data | Q24616873 | ||
| The rising incidence of idiopathic pulmonary fibrosis in the U.K | Q28236424 | ||
| Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis | Q28283421 | ||
| Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis | Q28291143 | ||
| An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management | Q28308246 | ||
| Muc5b is required for airway defence | Q28589969 | ||
| The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis | Q28728072 | ||
| Improved detection of bifidobacteria with optimised 16S rRNA-gene based pyrosequencing | Q28730885 | ||
| Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis | Q28943334 | ||
| Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study | Q28943525 | ||
| Search and clustering orders of magnitude faster than BLAST | Q29547431 | ||
| Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons | Q29614292 | ||
| PyNAST: a flexible tool for aligning sequences to a template alignment | Q29616628 | ||
| UniFrac--an online tool for comparing microbial community diversity in a phylogenetic context | Q29622870 | ||
| Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study | Q30384494 | ||
| Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. | Q31134621 | ||
| Statistical methods for detecting differentially abundant features in clinical metagenomic samples | Q33429043 | ||
| Accurate determination of microbial diversity from 454 pyrosequencing data | Q33492259 | ||
| Disordered microbial communities in the upper respiratory tract of cigarette smokers | Q33781228 | ||
| Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis | Q34275871 | ||
| Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts | Q34412019 | ||
| Upper airways microbiota in antibiotic-naïve wheezing and healthy infants from the tropics of rural Ecuador | Q34447480 | ||
| Genetics in pulmonary fibrosis--familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis | Q35010171 | ||
| A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. | Q35049328 | ||
| Viral infection in acute exacerbation of idiopathic pulmonary fibrosis | Q35107245 | ||
| Respiratory microbiome in IPF: cause, effect, or biomarker? | Q35157806 | ||
| The lung tissue microbiome in chronic obstructive pulmonary disease | Q35987112 | ||
| A common MUC5B promoter polymorphism and pulmonary fibrosis. | Q36048530 | ||
| Is idiopathic pulmonary fibrosis an environmental disease? | Q36493941 | ||
| Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? | Q36989280 | ||
| Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome | Q37769355 | ||
| Clinical course and prediction of survival in idiopathic pulmonary fibrosis | Q37799183 | ||
| An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease | Q38006923 | ||
| The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. | Q38133505 | ||
| Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial | Q44137651 | ||
| Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis | Q47878148 | ||
| A mathematical theory of communication | Q56580111 | ||
| Idiopathic pulmonary fibrosis | Q56764887 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bacteria | Q10876 |
| pulmonary fibrosis | Q32446 | ||
| pathogenesis | Q372016 | ||
| idiopathic pulmonary fibrosis | Q2290446 | ||
| P304 | page(s) | 906-913 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis | |
| P478 | volume | 190 |
| Q41034398 | 13th ERS Lung Science Conference. The most important take home messages: News from the Underground |
| Q92987830 | A Facile Profiling Method of Short Chain Fatty Acids Using Liquid Chromatography-Mass Spectrometry |
| Q90633276 | A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis |
| Q43178545 | A first glimpse at the early origins of idiopathic pulmonary fibrosis |
| Q91784404 | A pathologic two-way street: how innate immunity impacts lung fibrosis and fibrosis impacts lung immunity |
| Q55528534 | A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis. |
| Q38448525 | Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies |
| Q43062781 | Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies? |
| Q46539385 | Airway Microbiota Determines Innate Cell Inflammatory or Tissue Remodeling Profiles in Lung Transplantation |
| Q40789565 | Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. |
| Q46259966 | Airway microbiota across age and disease spectrum in cystic fibrosis |
| Q49381015 | Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung. |
| Q64944665 | Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients. |
| Q43211086 | An investigation of canine leptospiral antibodies in Tokyo and Yokohama. Comparison of Canine Positive rates between rapid microscopic agglutination test and Schüffner-Mochtar test |
| Q38664600 | Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? |
| Q47937434 | Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? |
| Q59129403 | Aspiration techniques for bronchoalveolar lavage in translational respiratory research: Paving the way to develop novel therapeutic moieties |
| Q37149994 | Association Between the MUC5B Promoter Polymorphism rs35705950 and Idiopathic Pulmonary Fibrosis: A Meta-analysis and Trial Sequential Analysis in Caucasian and Asian Populations |
| Q92666206 | Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected] |
| Q98882102 | Azithromycin: The First Broad-spectrum Therapeutic |
| Q92931424 | Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent |
| Q52371735 | Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection. |
| Q36321964 | Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa |
| Q37094624 | CT Imaging Phenotypes of Pulmonary Fibrosis in the MUC5B Promoter Site Polymorphism |
| Q38480847 | CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society |
| Q37733049 | Calpain 1 regulates TGF-β1-induced epithelial-mesenchymal transition in human lung epithelial cells via PI3K/Akt signaling pathway |
| Q42325050 | Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. |
| Q36222034 | Clinical Features and Outcomes of IPF Patients Hospitalized for Pulmonary Infection: A Japanese Cohort Study. |
| Q54213046 | Clinical Genetics in Interstitial Lung Disease. |
| Q38273636 | Combination therapy: the future of management for idiopathic pulmonary fibrosis? |
| Q37345980 | Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. |
| Q36163849 | Data Mining of Lung Microbiota in Cystic Fibrosis Patients |
| Q90274449 | Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical |
| Q60044802 | Effects of smoking on the lower respiratory tract microbiome in mice |
| Q36045589 | Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan. |
| Q51760494 | Fibrosis: Lessons from OMICS analyses of the human lung. |
| Q43191540 | Follow-up chest radiographic findings in patients with MERS-CoV after recovery. |
| Q58116441 | Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis |
| Q40787967 | Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation |
| Q107473554 | Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs |
| Q39022184 | Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. |
| Q46732468 | Host-Microbial Interactions: Idiopathic Pulmonary Fibrosis in Technicolor |
| Q55558258 | How low can we go? The implications of low bacterial load in respiratory microbiota studies. |
| Q40134859 | IPF: Moving from Idiopathic to Infectious Pulmonary Fibrosis? |
| Q38821078 | Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways |
| Q47901631 | Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies |
| Q37013159 | Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. |
| Q87721963 | Idiopathic pulmonary fibrosis |
| Q89691744 | Idiopathic pulmonary fibrosis |
| Q26776473 | Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history |
| Q50326794 | Idiopathic pulmonary fibrosis: pathogenesis and management. |
| Q90228264 | Imaging Review of the Lung Parenchymal Complications in Patients with IPF |
| Q90334361 | Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis? |
| Q39021308 | Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis |
| Q94645685 | Immunological fortification at our barrier organs: Protecting us as we age |
| Q87898913 | Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis |
| Q38948397 | In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β. |
| Q38461691 | Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea |
| Q38913044 | Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis |
| Q51423230 | Innate immune signaling and stem cell renewal in idiopathic pulmonary fibrosis. |
| Q47658743 | Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. |
| Q58735224 | Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial |
| Q92044820 | Ironing Out the Roles of Macrophages in Idiopathic Pulmonary Fibrosis |
| Q64076177 | Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis |
| Q92743108 | Looking at the Airway to Understand Interstitial Lung Disease |
| Q97420817 | Low IgA Associated With Oropharyngeal Microbiota Changes and Lung Disease in Primary Antibody Deficiency |
| Q59359589 | Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation |
| Q91793493 | Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis |
| Q33897430 | Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ. |
| Q35736479 | Lungs, microbes and the developing neonate |
| Q36490141 | MUC5B and Idiopathic Pulmonary Fibrosis |
| Q40491886 | MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. |
| Q38981232 | Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis |
| Q38708801 | Microbiome in interstitial lung disease: from pathogenesis to treatment target |
| Q38627783 | Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. |
| Q99582945 | Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms |
| Q26864836 | Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers |
| Q60044254 | Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice |
| Q90482381 | Mucins and their receptors in chronic lung disease |
| Q90080269 | Mucins as a New Frontier in Pulmonary Fibrosis |
| Q92599322 | Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison |
| Q47734944 | New opportunities for managing acute and chronic lung infections |
| Q39330304 | New treatment directions for IPF: current status of ongoing and upcoming clinical trials. |
| Q38679715 | Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians |
| Q38725808 | Novel Drug Targets For Idiopathic Pulmonary Fibrosis. |
| Q89564976 | Of Mice and Men . . . and Microbes: Conclusions and Cautions from a Murine Study of the Lung Microbiome and Microbiome-Immune Interactions |
| Q46683677 | Outside In: Sequencing the Lung Microbiome |
| Q38851479 | Pharmacogenetics and interstitial lung disease |
| Q26748808 | Pharmacological management of IPF |
| Q26738458 | Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy |
| Q47704287 | Potential Role of the Lung Microbiome in Shaping Asthma Phenotypes |
| Q33714064 | Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis |
| Q54321179 | Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love? |
| Q41557420 | Protected sampling is preferable in bronchoscopic studies of the airway microbiome |
| Q92661762 | Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis |
| Q26745905 | Recent advances in understanding idiopathic pulmonary fibrosis |
| Q97525703 | Regeneration and repair in the healing lung |
| Q90507291 | Respiratory microbiome and epithelial interactions shape immunity in the lungs |
| Q38702812 | Respiratory microbiota and lower respiratory tract disease. |
| Q37085155 | Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis |
| Q90537703 | Risk factors for the development of idiopathic pulmonary fibrosis: A review |
| Q95355760 | Role of Microbial Agents in Pulmonary Fibrosis |
| Q47557151 | Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. |
| Q41987385 | Role of microbiota on lung homeostasis and diseases. |
| Q37712548 | Sepsis risk factors in infants with congenital diaphragmatic hernia. |
| Q36095068 | Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. |
| Q47221291 | Stimulator of Interferon Genes Deficiency in Acute Exacerbation of Idiopathic Pulmonary Fibrosis |
| Q40949850 | Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. |
| Q35868426 | Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach |
| Q36516894 | TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis |
| Q42580526 | Taking the "I" out of IPF. |
| Q37080510 | Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? |
| Q64072725 | The Challenging Road of Moving from Association to Causation for Microbiome Research in Idiopathic Pulmonary Fibrosis |
| Q38538384 | The Lung Immune Response to Nontypeable Haemophilus influenzae (Lung Immunity to NTHi). |
| Q47282447 | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
| Q38853672 | The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease |
| Q35687192 | The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease |
| Q88039580 | The Lung Microbiota of Healthy Mice Are Highly Variable, Cluster by Environment, and Reflect Variation in Baseline Lung Innate Immunity |
| Q35829947 | The Microbiome and the Respiratory Tract |
| Q53577355 | The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air. |
| Q52332667 | The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. |
| Q35677622 | The bacterial microbiota in inflammatory lung diseases |
| Q33820414 | The development of lower respiratory tract microbiome in mice |
| Q90003618 | The influence of the microbiome on respiratory health |
| Q47693431 | The lung microbiome in health and disease. |
| Q46825127 | The lung microbiome in idiopathic pulmonary fibrosis. What does it mean and what should we do about it? |
| Q38542375 | The microbiome of the human lower airways: a next generation sequencing perspective |
| Q39402027 | The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know? |
| Q33601748 | The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes |
| Q91940320 | The protective effects of bone mesenchymal stem cells on paraquat-induced acute lung injury via the muc5b and ERK/MAPK signaling pathways |
| Q59355576 | The pulmonary microbiome: challenges of a new paradigm |
| Q88129968 | The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis |
| Q33871544 | The respiratory microbiome in idiopathic pulmonary fibrosis |
| Q38783008 | The respiratory tract microbiome and lung inflammation: a two-way street |
| Q47770768 | The role of periostin in lung fibrosis and airway remodeling |
| Q40463304 | Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF. |
| Q26779192 | Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs |
| Q38631673 | Update in Interstitial Lung Disease 2014. |
| Q28081676 | Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation |
Search more.